Clinical Report: Predictive Value of Albumin-to-Creatinine Ratio on Mortality

Overview

This study investigates the relationship between albumin-to-creatinine ratio (ACR) and mortality in U.S. adults with metabolic dysfunction-associated steatotic liver disease (MASLD). ACR serves as a potential mediator linking diabetes and hypertension to mortality, highlighting its importance in risk stratification for this population.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health concern, closely linked to obesity and other metabolic disorders. Understanding the prognostic value of biomarkers like ACR in MASLD can enhance risk stratification and inform clinical management strategies. Given the high prevalence of MASLD and its association with cardiovascular and renal complications, identifying effective predictors of mortality is crucial.

Data Highlights

This study utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018, focusing on participants diagnosed with MASLD based on established definitions.

Key Findings

• ACR is a significant predictor of mortality in adults with MASLD.
• Elevated ACR, even within normal ranges, correlates with increased cardiovascular and metabolic risks.
• ACR mediates the relationship between diabetes, hypertension, and mortality outcomes.
• Hepatic fibrosis status is a critical factor influencing the relationship between ACR and long-term outcomes in MASLD patients.
• The study analyzed a total of 4,312 participants meeting the criteria for MASLD based on the Fatty Liver Index.

Clinical Implications

Healthcare professionals should consider ACR as a valuable biomarker for assessing mortality risk in patients with MASLD. Regular monitoring of ACR can aid in identifying high-risk individuals, allowing for timely interventions and management of comorbid conditions.

Conclusion

The findings underscore the importance of ACR in predicting mortality among individuals with MASLD, suggesting its potential role in enhancing clinical decision-making and patient management strategies.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Introducing AGA’s new MASLD clinical care pathway - American Gastroenterological Association
6. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 - PMC
7. Introducing AGA’s new MASLD clinical care pathway - American Gastroenterological Association
8. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 - PMC
9. https://bmcgastroenterol.biomedcentral.com/counter/pdf/10.1186/s12876-025-04440-7.pdf